Weight-loss medications, such as Wegovy, are being researched for potential use in dogs as a means of combating obesity-related health issues. These drugs mimic the hormone GLP-1, which helps reduce appetite. A biotech company has begun trials for an implant that could replicate this effect in dogs, aiming for market release by 2028. With 50% of dogs and 43% of cats reported overweight, experts highlight that excess weight can lead to serious health concerns, stressing the need for increased exercise and disciplined feeding before considering medication as an option.
The active ingredients in weight-loss medications like Wegovy mimic GLP-1, reducing appetite in humans and could potentially be adapted for dogs.
Biotech firms are investigating weight-loss drugs for dogs, with hopes of alleviating obesity-related health issues prevalent in various breeds.
About 50% of dogs and 43% of cats in the UK are reported overweight, leading to serious health concerns like diabetes and heart disease.
Veterinary experts advocate for increased exercise and dietary discipline as primary solutions for managing pet obesity before considering pharmaceutical options.
Collection
[
|
...
]